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Background: The periacetabular area is one of the primary sites of metastatic tumors, which often present as
osteolytic bone destruction. Bone destruction in the acetabulum caused by metastatic tumors will cause hip pain
and joint dysfunction. It results in decreased quality of life for patients. The aim of our study was to explore the
clinical effect of metastatic periacetabular tumors treated with percutaneous cementoplasty and interstitial
implantation of 125I seeds.
Methods: A retrospective analysis was performed on 24 patients with metastatic periacetabular tumors who
underwent combined therapy of percutaneous acetabuloplasty and interstitial implantation of 125I seeds between
February 2003 and June 2011. There were 13 males and 11 females aged 19–80 years with a mean age of 57.3. The
primary tumor site was the lung in eight cases, the breast in six, the prostate cancer in eight, and the liver in two.
The amount of implanted 125I seeds was 12–20 seeds/person, with a mean of 16.5 seeds/person, and the matching
peripheral dosage (MPD) was 80~100Gy. Routine postoperative chemotherapy and other combined treatments
were applied to patients after the surgical operation. Changes in the Karnofsky Score(KPS), Harris Hip Score(Harris),
and Visual Analog Scale(VAS) were observed during the follow-up period.
Results: The 24 patients’ operations were all successful. No major complications occurred. Complete pain relief was
achieved in 58% (14 of 24) of patients, and pain reduction was achieved in the 42% remaining (10) patients. The
mean duration of pain relief was 8.3 months. Pain recurred in one patient 3 months after surgery. Six patients had
died and 18 patients were alive at the time of the 1-year follow-up. Comparing the KPS, Harris and VAS scores pre-
and postoperativelyat 1, 6, and 12 months, the combined therapy method was significantly effective in metastatic
periacetabular tumor patients (P<0.05).
Conclusions: Percutaneous cementoplasty with interstitial implantation of 125I seeds is an effective treatment
method for metastatic periacetabular tumor patients, providing tumor resistance, pain relief, increased bone
stability, and improved quality of life for patients.
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The periacetabular area is one of the primary sites of
metastatic tumors, which often present as osteolytic
bone destruction. Bone destruction in the acetabulum
caused by metastatic tumors causes hip pain and joint
dysfunction, resulting in decreased quality of life for the
patients [1].
Radiotherapy and surgery are the commonly used
methods to treat acetabular metastases. Radiotherapy
achieves pain relief rate in 75% or more of the patients
with metastatic tumors, but marked clinical improve-
ment is observed in all patients 1 or 2 weeks after radio-
therapy. However, radiotherapy cannot cure structural
weakening of the pelvis caused by tumors and also leads
to regional osteoporosis caused by radiotherapy, which
increases the incidence of pathological fractures [2,3].
Harrington and colleagues [4] showed that hip recon-
struction for periacetabular metastasis could improve
the functional status and reduce pain. For reconstruc-
tions of the hip joint and bone defect repairs, maintain-
ing the normal lines of force needs to be considered
when operating. Because of the poor general condition
of patients, complexity of the operative process, and
large wounds, reconstruction can involve the complica-
tions of local recurrence, deep infections, dislocations,
and fractures of the internal implant in the perioperative
period [5-11]. Extensive resection and reconstruction
usually bring more risks than advantages and are not the
preferred operative option [12]. Instead, tumor curettage
and bone cement sometimes achieve better results.
Percutaneous acetabuloplasty is the injection of acrylic
bone cement into malignant or benign bone cavities in
order to relieve pain and/or stabilize the bone. Bone
packing with cement aims to treat or prevent vertebral
and extraspinal pathological fractures and relieve pain in
patients with osteoporosis and bone metastases, which,
if applied in the treatment of acetabular metastases after
surgery, could effectively improve the patients' quality of
life [13-15].
125I particle implantation, as an effective interstitial
brachytherapy (IBT) technique, has been widely reported
recently. Interstitial brachytherapy refers to the implant-
ation of radioactive sources, usually in the form of nee-
dles, seeds, or wires, which are directly injected into the
tumor lesion. Radioactive seed implantation has the
advantages of real-time monitoring, precise orientation,
being a simple operation, causing no radiation injury,
etc., which can efficiently improve local control or in-
crease the survival rate of patients with bone metastases
[16-18]. The aim of this technique is to tailor the dose
of irradiation to the anatomy of the patient for a better
target volume coverage.
The aim of our study was to evaluate the efficacy of
percutaneous puncture of the bone cement combinedwith 125I seed implantation in the treatment of 24
patients with acetabular metastases enrolled from Febru-
ary 2003 to June 2011.Methods
Patients
Twenty-four patients with periacetabular metastatic
tumors were treated using percutaneous puncture of the
bone cement combined with 125I particle implantation
from February 2003 to June 2011. We obtained approval
for the study from the Ethics Committee of Tumor Hos-
pital of Yunnan Province. The subjects and their families
were well informed of the details and signed relevant
contracts prior to the study. Patient ages ranged from 18
to 80 years; follow-upduration ranged from 8 to 60
months. There were single periacetabular metastases in
8 patients and and multiple bone metastases accompan-
ied by periacetabular metastases in 16 patients. In 6
cases the primary tumors metastasized after resection in
6 months to 7 years; in 13 patients the primary tumor
metastasized after radiotherapy and biological treatment
within about 6 months to 2 years. Pain from the first
metastasis occurred in five patients, and the primary ma-
lignancy site was found after inspection. The demo-
graphic data and primary malignancy site are shown in
Table 1.
Participants were patients with the following condi-
tions: (1) the pathology had been confirmed by cytology
in malignant tumor patients; (2) expected survival time
of over 3 months; (3) persistent periacetabular pain, and
no significant improvement achieved after medication
and/or physical therapy. They also had confirmed peria-
cetabular osteolytic destruction after X-ray, CT, and
MRI imaging assessment.
Indications and contraindications for percutaneous
acetabuloplasty and 125I seed implantation according to
Maccauro [19] are detailed in Table 2.
Table 2 Indications and contraindications for









Life expectancy ≥3 months 2: Relative contraindications
Inability to tolerate major
surgery
Radiographic signs of medial wall
interruption
Ineffective radiotherapy Local infection
Hemorrhagic disorders
Figure 1 Right margin of the acetabulum in metastatic breast
cancer before the operation.
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A domestic bone cement valvuloplasty device was used
in our evaluation; the device included a puncture needle
and a precession type injector pressure device (Guan
Long Company, Shandong, China). A closed radioactive
isotope 125I source was selected as the radioactive source
(China Institute of Atomic Energy Isotopes, Beijing;
Chinese Drug Approval No. H20045969). The radiation
source is cylindrical, and the diameter and height are
0.8 mm and 4.5 mm, respectively, with tissue-penetrating
ability of 1.7cm and a half value layer of 0.025 mmPb. It
is surfaced with titanium alloy inclusions, with a source
activity of 0.3−1 mci. Liquid immersion disinfection was
selected using benzalkonium bromide (soaked in Bromo-
geramine solution for 30 min).
Treatment planning system
The treatment planning system was provided by Nuclear
Industry Corp., Beijing Kelinzhong Medical Technology
Institute. CT/MRI image scan results were obtained
with three-dimensional digital image reconstruction in
each patient before treatment using the system software
according to lesion size, location, and the relationship
with surrounding normal tissues. Three-dimensional
icons and isodose curves were drawn to indicate the pre-
cise formulation and absorbed dose. At the same time,
the radiation source initial dose, applicator needle co-
ordinate, and depth indicator were given, and the treat-
ment plan form was printed out. The initial dose of 125I
particles was 2.92cGy/h/particles, and the 90% isodose
curve included 90% tumor target volume. The tumor
periphery matching dose (MPD) was 80 to100Gy.
Surgical technique
Routine tests of preoperative cardiopulmonary function,
blood glucose, blood coagulation, liver and kidney func-
tion, and iodine allergy were conducted before the oper-
ation. The extent of lesions was determine by X-ray, CT,
or MRI examination (Figure 1) to choose the optimal
operation line. The interventional operations wereconductedusingDSA machine guidance under sterile
conditions; all patients received analgesic treatment 15
min before the operation.
Steps
Step 1: A lateral patient position was required to
confirm the lesion locationusing DSA. The
needle was disinfected with 1% lidocaine. The
puncture needle was always perpendicular to
the cortical bone destruction area in order to
facilitate the puncture.
Step 2: The puncture needle was inserted into the
bone fracture zone in an open perspective, then
was pulled out. 125I particles were implanted
according to the preoperative TPS treatment
planning with an injection distance of 0.3 cm. A
beveled needle and changed needle puncture
direction were used for optimal implantation of
the 125I particles.
Step 3: The needle core was taken out, and the
puncture needle was left in the target area;
5 ml of contrast was injected through the
needle, and the contrast medium flow was
record by DSA. Polymethyl methacrylate
(PMMA) was used as bone cementand was
mixed with non-ionic contrast medium during
the operation; the injection was conducted
under fluoroscopic monitoring to prevent bone
cement leakage to the bone (Figure 2).
Step 4: The puncture needle was placed in the cortical
bone after injection. The needle core was
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cement. The needle was pulled out before bone
cement hardening. The amount of bone
cement injected was 4 to 11 ml; the average
amount was 5.5 ml. X-rays (Figure 3) and CT
scans (Figure 4) were conducted after 15 to 20
min to determine when the bone cement
polymerization reaction was complete. The
number of 125I particles implanted was 12 to
20; the average number was 16.5.Figure 3 Postoperative radiographic review showing good 125I
particle distribution and bone cement filling.Evaluation of therapeutic outcomes
Main outcomes were measured as:
 Postoperative observation of symptoms, change of
signs, infection, or bone cement leakage.
 Preoperative and postoperative pain ratings of
patients with follow-up and application of narcotic
analgesic drugs.
 The Karnofsky Performance Status (KPS) physical
status score, the Harris Hip Scale (Harris) score for
hip function, and the Visual Analog Scale (VAS) for
pain were recorded 1,6 and 12 months before and
after the operation in all patients.Statistical analysis
Basic statistical analyses were performed using the SPSS
20.0 statistical software (SPSS Inc., Chicago, IL, USA).
Categorical data were given as total numbers (and/or rela-
tive frequencies). Continuous data were given as mean ±
standard deviation. Student’s t-test was performed toFigure 2 Percutaneous injection of bone cement combined
with 125I particle implantation using a DSA machine guide.compare means between two groups. A value of P<0.05
was considered statistically significant.Results
All 24 patients’ operations were successful. CT scan
results showed bone cement and 125I particle distribution
in tumor foci in the central region presenting as a mass or
diffuse distribution (Figures 3,4). A small amount of
PMMA leaked after bone cement injection angioplasty inFigure 4 Postoperative CT shows bone cement filling of the
cortical bone destruction area.
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no need for special treatment.
No periacetabular fractures, increased local lesions,
radioactive enteritis, or local wound inflammation oc-
curred during follow-up. Narcotic analgesic drug abuse
was alleviated compared to before the operation and disap-
peared in some patients. Ten patients died in the 3-month
follow-up period; one died 3 months after the operation,
two died 6 months after the operation, and three died 1
year after the operation. Four other patients died after the
3-year follow-up. They all died of other visceral metastases.
Continued general improvement was achieved accord-
ing to the KPS physical status score evaluation. The
average KPS scores were 49.63± 10.45, 81.18 ±17.59, and
83.75± 32.60 preoperatively and 1 and 6 months after
the operation, respectively. The KPS physical status
score decreased 12 months after the operation, with an
average score of 72.77± 43.09, showing a worse result in
patients with physical conditions; 6 patients died 12
months after the operation (Table 3, Figure 5).
The Harris hip score reflected the general change in
patients in activities of daily living. The score increased
from 33.94 ±2.92 before the operation to 71.32± 16.57 1
months after the operation, and further improved to 83.24±
32.53 6 months after the operation. The score decreased to
71.70±42.63 1 year after the operation, but was still higher
than the preoperative score (Table 3, Figure 6).
Similar trends were seen in patient’s VAS pain score.
The pain score decreased from 7.80± 0.42 preoperatively
to 3.11± 0.57 1 month postoperatively and continued to
decrease to 2.03±0.99 6 months after the operation. This
increased to 3.24 ±2.35 1 year after the operation
(Table 3, Figure 7).
Statistical analysis results showed statistical signifi-
cance with P< 0.05 for the KPS, Harris, and VAS scores
1, 6, and 12 months before and after the operation
(Table 3, Figure 2). In 58% of patients (14 cases) local
pain disappeared completely, and pain was alleviated in
42% of patients (10 cases). The pain relief duration was
8.3 months.The pain recurred 3 months after the oper-
ation in one patient.
Discussion
Acetabular metastases are a common and severe complica-
tion in advanced malignant disease. The major complicationsTable 3 Changes in the Visual Analog Scale(VAS), Harris Hip S
Value Preoperative Postoperati
1 months 6 months
KPS 49.63±10.45 81.18±17.59 83.75±32.60
Harris 33.94±2.92 71.32±16.57 83.24±32.53
VAS 7.80±0.42 3.11±0.57 2.03±0.99
P1, P2, and P3 are 1,6, and 12 months after the operation, respectively.associated with bone involvement are severe pain and bone
destruction, all of which restrict mobility and greatly reduce
the patient’s quality of life. Periacetabular metastatic tumor
treatment involves abalance of survival, function, and qual-
ity of life, with limited life expectancy for the patients. Joint
function and quality of life are limited, too [20].
Bone destruction in the acetabulum caused by meta-
static tumors will cause the femoral head togradually
shift toward the medial and top of the acetabulum, the
occurrence of pathological fractures, or joint collapse.
This can even cause the patient become completely bed-
ridden, increase the chance of pressure sores and hypo-
static pneumonia, and seriously influence the patient's
quality of life. According to the Enneking partition
standard for pelvic tumors [21], periacetabular tumors,
which are classified as region lII tumors, are usually
widely resected, which has important treatment implica-
tions for primary acetabular malignant tumors. However,
there is no direct relationship between acetabular resec-
tion and the survival rate of patients with metastatic
tumors; this is meaningful for alleviating the symptoms
and improving function. Effective treatment should re-
lieve the patient’s pain and reconstruct the acetabulum
bony structure, enhance the acetabular bearing capacity,
and recover walking function [22].
With the injection of bone cement to the acetabular
bone destruction zone through percutaneous puncture,
we were able to improvethe patients’ functional status
and reduce pain. This restored the bone's mechanical
properties in the region of the operation immediately,
enhanced the local skeletal resistance capacity, reduced
the occurrence of pathological fractures, and enhanced
the bone’s local stability.
The cytotoxicity of the PMMA bone cement monomer
causes tumor cells to dehydrate, solidify, and undergo
apoptosis; the polymerization process releases large
amounts of heat up to 72 to 78°C. Because of the ther-
mal effects, the tumor tissue and spinal nociceptive
nerve endings become necrotic. Solidification of the
bone cement increases the bone’s stability and support-
ive ability.It can reduce pain caused by stimulation of
nerve endings, cut off the tumor’s blood supply, and fi-
nally cause tumor tissue necrosis.
Cotton [23] first applied the technology to the treat-
ment of acetabular metastases in 1995, reporting 11core(Harris), and Karnofsky Score(KPS) scores
ve P value
12 months P1 P2 P3
72.77±43.09 0.000 0.000 0.006
71.70±42.63 0.000 0.000 0.000
3.24±2.35 0.000 0.000 0.000
Figure 7 Changes in the Visual Analog Scale (VAS).Figure 5 Changes in the Karnofsky Score (KPS).
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cementoplasty. The pain decreased by 81.8% after 1 to
5days of treatment. Walking function improved in all
patients except in one patient,who reported increased
pain caused by acetabular fractures. Marcy [13] reported
12 cases of follow-up results of acetabular metastasis in
patients 4.6 months after the operation. Pain relief and
walking function improved significantly, and one patient
had an acetabular fracture 15 days after the operation.
Subsequent studies reported satisfactory effects of bone
cementoplasty on percutaneous puncture in the treat-
ment of acetabular metastases in the short- and long-
term [24,25].
125I particle radiotherapy includes external beam therapy
(EBRT) and interstitial brachytherapy (IBT). EBRT
requires higher radiation doses to achieve the effect becau-
seperipheral organs affectthe tumor tissue localization.
EBRT only works well before tumor metastasis and its effi-
cacy decreases with tumor cell mitosis [16,17]. IBT can
maximize the results of irradiation while causing
minimal radiation injury of the surrounding normal
tissue [18].
125I seed implantation is a highly effective treatment
for patients with localized cancer. With the advantagesFigure 6 Changes in the Harris Hip Score (Harris)of a relatively short half-life, use of low-energy photons
with a low risk of complications, and the accuracy and
consistency of the seeds, 125I seed implantation has been
widely used for treatment of all kinds of solid tumors
[26,27].
Combined therapy using percutaneous radiofrequency
ablation (RFA) and cementoplasty has been shown to be
a safe and effective technique for palliative treatment of
painful neoplastic bone metastasis [28,29]. In our study
of 24 cases of acetabular metastases in patients with per-
cutaneous puncture treated with bone cement combined
with 125I seed implantation, the pain disappeared com-
pletely in 58% (14 cases) of patients and was alleviated
in 42% (10 cases) of patients after the operation, with
the average duration of pain relief being 8.3 months, ex-
cept for pain recurrence in one patient 3 months after
the operation. Statistical analysis results for the KPS,
Harris and VAS scores before and after 1,6, and 12
months showed significant differences. No acetabular
fractures or increase of local lesions was found on post-
operative follow-up, and the phenomenon of abusing
narcotic analgesic drugs was alleviated. However, it is
difficult to evaluate narcotic drug use effects systematic-
ally, because patients might abuse drugs because of pain
caused by tumor metastasis.
Percutaneous puncture of the bone cement combined
with 125I seed implantation plays an important role in
the treatment of metastatic bone tumors. Our early
study results of 40 patients with spinal metastases
showed good clinical results [30]. The results of applying
the combined technology for periacetabular metastatic
tumor treatment showed that the combined operation
therapy is effective for periacetabular metastatic tumors.
Conclusions
The combined therapy has antineoplastic characteristics,
relieving pain and enhancing skeletal stability. It is a good
option to control the development of local tumors and
Zhang et al. World Journal of Surgical Oncology 2012, 10:250 Page 7 of 7
http://www.wjso.com/content/10/1/250improve patients’ quality of life. Further observation is
being conducted to evaluate the prolongation of survival
time.
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